Agenus Inc., listed on NASDAQ under the ticker AGEN, is a pioneering immuno-oncology company focused on developing innovative treatments to activate the immune system against cancer. The company's extensive pipeline includes immune checkpoint antibodies, adoptive cell therapies, and cancer vaccines, all designed to enhance the body's natural defenses to fight cancer. Agenus serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, operating primarily in the biotechnology and pharmaceutical markets.

The business model of Agenus revolves around research and development, clinical trials, and strategic partnerships. Revenue is generated through licensing agreements, milestone payments, and royalties from its proprietary technologies and therapies. The company also engages in collaborations with other biotech firms and academic institutions to advance its research and expand its therapeutic offerings.

Agenus aims to address unmet medical needs in oncology by providing cutting-edge therapies that improve patient outcomes and quality of life. The company is committed to advancing its pipeline through rigorous clinical trials and regulatory approvals, ensuring that its treatments are both safe and effective.

Keywords: immuno-oncology, checkpoint antibodies, cell therapies, cancer vaccines, immune response, biotechnology, clinical trials, strategic partnerships, oncology treatments, NASDAQ AGEN.